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ABSTRACT
M . D . E N G L E N , P . J . F E D O R K A - C R A Y , S . R . L A D E L Y A N D D . A . D A R G A T Z . 2005.

Aims: This study examined 448 Campylobacter strains isolated in 1999 and 2000 from US feedlot cattle for
resistance to 12 antimicrobials.
Methods and Results: Isolates were tested for antimicrobial susceptibility using the E-test method. Approximately 60% (n ¼ 267) were resistant to one or more antimicrobials, and 19Æ6% (n ¼ 88) were resistant to two or
more antimicrobials. Of the Campylobacter jejuni isolates, 49Æ1% (n ¼ 187) were resistant to tetracycline, 10Æ2%
(n ¼ 39) were resistant to nalidixic acid, 8Æ4% were resistant to trimethoprim/sulfamethoxazole, and 1Æ8% (n ¼ 7)
were resistant to ciprofloxacin. Resistance to any of the other eight antimicrobials was 1Æ3% or less, but 14Æ4%
(n ¼ 55) were resistant to two or more antimicrobials. In the Campylobacter coli group, 65Æ7% (n ¼ 44) were
resistant to tetracycline, 52Æ2% (n ¼ 35) were resistant to trimethoprim/sulfamethoxazole, 22Æ4% (n ¼ 15) were
resistant to nalidixic acid, and 9Æ0% (n ¼ 6) were resistant to ciprofloxacin. Resistance to any of the remaining eight
antimicrobials was 3Æ0% or less, although 49Æ3% (n ¼ 33) were resistant to two or more antimicrobials.
Conclusions: Although antimicrobials are widely used in US feedlot cattle production, our results demonstrate
generally low levels of resistance to a broad range of commonly used antimicrobials relative to other recent studies.
Significance and Impact of the Study: Resistance data on Campylobacter isolated from this major US livestock
commodity is lacking. This overview enhances current knowledge and provides a basis for further studies.
Keywords: antimicrobials, Campylobacter coli, Campylobacter jejuni, cattle, resistance.

INTRODUCTION
Campylobacter is recognized as a major cause of acute
bacterial gastroenteritis in humans worldwide (Friedman
et al. 2000). Clinical signs include abdominal pain, fever,
malaise, nausea, vomiting and diarrhoea (Skirrow and Blaser
2000). Most patients recover in less than a week, but up to
20% may relapse or experience prolonged or severe illness
*The mention of trade names or commercial products in this manuscript is solely for the
purpose of providing specific information and does not imply recommendation or
endorsement by the US Department of Agriculture.
Correspondence to: Mark D. Englen, USDA, Agricultural Research Service,
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requiring antibiotic therapy. Two species of Campylobacter,
C. jejuni and C. coli, are most frequently isolated from cases
of human infection (Engberg et al. 2000).
A number of studies have investigated the epidemiology
of Campylobacter in poultry breeder and broiler operations
(van de Giessen et al. 1992; Humphrey et al. 1993; JacobsReitsma 1995, 1997, 2000; Pearson et al. 1996), and poultry
products are considered to be a main source of Campylobacter infections in humans (Deming et al. 1987; Doyle and
Jones 1992). Prevalence studies have also shown that
Campylobacter is a common commensal in cattle (Garcia
et al. 1985; Manser and Dalziel 1985; Stanley et al. 1998;
Wesley et al. 2000). Accordingly, beef and dairy products
(especially raw milk) can be a source of human Campylobacter infection (Stern 1992; Headrick and Tollefson 1998).
This article is a U.S. government work, and is not subject to copyright in the United States.
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The emergence of strains of Campylobacter and other
food-borne bacterial pathogens resistant to antimicrobials
used to treat human disease has provoked controversy over
the use of antimicrobials in food animal production,
including extensive examination of its effects on antimicrobial resistance in these organisms (Khachatourians 1998;
Teuber 2001). Antimicrobial resistance in Campylobacter
isolated from the poultry production environment has been
well documented in studies from around the world (JacobsReitsma et al. 1994; Chuma et al. 2001; Heuer et al. 2001;
Van Looveren et al. 2001). In contrast, while cattle have
been included in multi-species investigations (Aarestrup
et al. 1997; Piddock et al. 2000), reports are lacking on
antimicrobial resistance in Campylobacter isolated from
cattle.
This study examined resistance to 12 common antimicrobials among a geographically diverse group of Campylobacter
strains isolated in 1999 and 2000 from US feedlot cattle.

from 67Æ1% (49 of 73) of all feedlots sampled with some
isolates from each of the 11 states where sampling occurred.
Cultures were streaked onto Campy-Cefex plates, and
incubated microaerobically for 48 h at 42C. Isolated
colonies were picked from these plates, streaked again onto
Campy-Cefex plates, and incubated microaerobically for
48 h at 42C. Isolated colonies from these plates were
streaked onto trypticase soya agar plates containing 5%
sheep’s blood (BA plates; B-D Biosciences, Sparks, MD,
USA), and incubated as before for 48 h at 42C. The BA
plates were used for isolate testing and to prepare additional
frozen stock cultures. Isolates were identified using the
Campylobacter BAX PCR (DuPont Qualicon, Wilmington,
DE, USA), a multiplex assay specific for C. coli and
C. jejuni. The assay was performed according to the
manufacturer directions as previously described (Englen
and Fedorka-Cray 2002).
Antimicrobial susceptibility testing

M A T E R I A LS A N D M E T H O D S
Study design, and bacterial isolation and
identification
The Campylobacter isolates used were collected as part of the
1999 National Animal Health Monitoring System study of
the health and management of US feedlot cattle (Feedlot
99; USDA 2000). The study focused on feedlots with 1000
head or more capacity as these facilities held over 80% of
US cattle as of February 1999. Faecal samples were obtained
from 73 feedlots in 11 major US feedlot states: California,
Colorado, Idaho, Iowa, Kansas, Nebraska, New Mexico,
Oklahoma, South Dakota, Texas and Washington. Samples
were collected during a 1-year period (October 1999 through
September 2000) from pen floors. For each feedlot, 25
samples were collected from three pens. Feedlots were
sampled twice during the 1-year collection period. Samples
were shipped for overnight delivery to the USDA-ARSARRU laboratory in Athens (GA, USA) for isolation of
Campylobacter and Salmonella.
For Campylobacter isolation, faecal samples were diluted
1 : 4 and 1 : 40 in phosphate-buffered saline. One hundredmicrolitre aliquots of each dilution were spread uniformly
on duplicate Campy-Cefex plates (Stern et al. 1992). The
plates were placed in zip-top bags and incubated microaerobically (5% O2, 10% CO2 and 85% N2) for 48 h at 42C.
Campylobacter was presumptively identified from microscope wet mounts of cells using phase contrast optics at
100·.
For the present study, a total of 448 isolates comprising
43Æ5% (448 of 1029) of all the Feedlot 99 Campylobacter
strains were randomly selected from among the frozen stock
Feedlot 99 culture collection. Isolates included were derived

Isolates were tested for antimicrobial susceptibility using the
E-test (AB-Biodisk, Piscataway, NJ, USA) according to the
manufacturer directions. This method has been adopted by
the National Antimicrobial Resistance Monitoring System
(NARMS) for susceptibility testing of Campylobacter, in
part, because it facilitates screening large numbers of
isolates. It has been shown to give results comparable with
other methods such as agar dilution for Campylobacter
(Luber et al. 2003; Oncul et al. 2003). In brief, 150 mm
Mueller–Hinton + 5% lysed horse blood plates (B-D
Biosciences) were inoculated with 100 ll of a cell suspension
equivalent to 1Æ0 McFarland standard. The inoculum was
swabbed evenly across the entire plate surface. E-test strips
were brought to room temperature from )20C storage
before use. Four strips were laid at 90 angles onto each
plate. The plates were placed in zip-top bags and incubated
microaerobically for 48 h at 42C. Following incubation, the
point at which the zone of growth inhibition intersected the
strip was read as the minimum inhibitory concentration
(MIC) of the antimicrobial in lg ml)1. Quality control
ATCC strains C. jejuni 33560, Escherichia coli 25922 and
Staphylococcus aureus 25923 were tested biweekly to confirm
susceptibility to all the antimicrobials. The antimicrobials
used in the study and the resistance breakpoints (MICs)
were: amoxicillin/clavulanic acid, ‡32; azithromycin, ‡2;
cefepime, ‡32; chloramphenicol, ‡32; ciprofloxacin, ‡4;
clindamycin, ‡4; erythromycin, ‡8; gentamicin, ‡16; imipenem, ‡16; nalidixic acid, ‡32; tetracycline, ‡16; trimethoprim/sulfamethoxazole, ‡32. With the exception of
cefepime, the MICs for the respective resistance breakpoints
were those used by NARMS as reported in the US Centers
for Disease Control NARMS 2001 Annual Report (http://
www.cdc.gov/narms/annuals.htm). For cefepime, the
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E-test manufacturer’s recommended resistance breakpoint
for anaerobes was used.
Data analysis
The antimicrobial resistance data was analysed using the
proportional hazard model (PHREG) in the SAS statistical
program (SAS Institute, Cary, NC, USA). This method
performs conditional logistic regression and provides
adjustment for the fact that the 448 isolates (i.e. observations) were not entirely independent. Rather, the isolates
were obtained from 73 different feedlots, with some
imbalance between the proportion of C. coli and C. jejuni
observed in each feedlot. This method and its applications
are discussed in detail by Allison (1999).

RESULTS
Antimicrobial resistance
Approximately 60% (n ¼ 267) of the 448 isolates included
in the study were resistant to one or more antimicrobials.
The percentages by species of isolates resistant to the
individual antimicrobials are shown in Table 1. The greatest
level of resistance observed was to tetracycline, at 51Æ6%
(n ¼ 231) for the test group as a whole. Resistance to
trimethoprim/sulfamethoxazole was next highest, at 15Æ0%
(n ¼ 67) overall, followed by nalidixic acid at 12Æ1%
(n ¼ 54). The isolates showed much less resistance to the
remaining nine antimicrobials. Among these, ciprofloxacin
resistance was the greatest, although reaching only 2Æ9%
(n ¼ 13). However, a number of differences in antimicrobial
resistance were observed between species (Table 1). In
particular, resistance in the C. coli group to nalidixic acid
Table 1 Percentage of Campylobacter isolates resistant to antimicrobials by species

Antimicrobial

C. jejuni
(n ¼ 381)

C. coli
(n ¼ 67)

Total
(n ¼ 448)

Amoxicillin/clavulanic acid
0
0
0
Azithromycin
0Æ8 (n ¼ 3) 1Æ5 (1)
0Æ9 (4)
Cefepime
1Æ3 (5)
1Æ5 (1)
1Æ3 (6)
Chloramphenicol
1Æ0 (4)
3Æ0 (2)
1Æ3 (6)
Ciprofloxacin
1Æ8 (7)
9Æ0* (6)
2Æ9 (13)
Clindamycin
1Æ0 (4)
1Æ5 (1)
1Æ1 (5)
Erythromycin
0Æ5 (2)
3Æ0 (2)
0Æ9 (4)
Gentamicin
0Æ25 (1)
0
0Æ2 (1)
Imipenem
0Æ25 (1)
1Æ5 (1)
0Æ4 (2)
Nalidixic Acid
10Æ2 (39)
22Æ4* (15) 12Æ1 (54)
Tetracycline
49Æ1 (187)
65Æ7 (44) 51Æ6 (231)
Trimethoprim/sulfamethoxazole 8Æ4 (32)
52Æ2* (35) 15Æ0 (67)
*Significantly higher resistance (P < 0Æ05) compared with C. jejuni.
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was more than twice as high as for the C. jejuni group
(22Æ4%, n ¼ 15 vs 10Æ2%, n ¼ 39; P < 0Æ05), and five times
higher for ciprofloxacin, compared with the C. jejuni strains
(9Æ0%, n ¼ 6 vs 1Æ8%, n ¼ 7; P < 0Æ05). Similarly,
resistance to trimethoprim/sulfamethoxazole was observed
in 52Æ2% of the C. coli (n ¼ 35) isolates, more than six times
that of C. jejuni (8Æ4%, n ¼ 32; P < 0Æ05). The C. coli
isolates were also more resistant to tetracycline than the C.
jejuni strains (65Æ7%, n ¼ 44 vs 49Æ1%, n ¼ 187), although
this difference was not significant at the 5% level.
Multiple resistance
Of the 448 isolates tested, 19Æ6% (n ¼ 88) were resistant to
two or more antimicrobials. A significantly higher percentage of the C. coli strains (49Æ3%, n ¼ 33; P < 0Æ05) belonged
to this group compared with the C. jejuni isolates (14Æ4%,
n ¼ 55). The majority of these 88 strains (71Æ6%, n ¼ 63)
were resistant to just two antimicrobials (Table 2). Of the
63 isolates resistant to two antimicrobials, 49Æ2% (n ¼ 31;
14 C. jejuni and 17 C. coli) combined resistance to tetracycline and trimethoprim/sulfamethoxazole. The next most
common pattern was resistance to nalidixic acid and
tetracycline, found in 39Æ7% (n ¼ 25; 24 C. jejuni and one
C. coli) of these strains. The remaining four patterns of
double resistance were comprised of three or fewer isolates.
Table 2 Resistance patterns of Campylobacter isolates resistant to two
or more antimicrobials (n ¼ 88)
No. of isolates with
resistance pattern

No. of
resistances

Resistance pattern

C. jejuni

C. coli

2
2
2
2
2
2
3
3
3
3
4
4
4
4
4
4
7

TC TS
NA TC
CI NA
PM TC
CM TC
EM TC
CI NA TC
NA TC TS
CI NA TS
PM TC TS
CI NA TC TS
AZ CL CM TC
EM IP TC TS
AZ CL EM TC
CM NA TC TS
CL NA TC TS
AZ CL CM EM NA PM TC

14
24
2
2
1
1
5
2
–
1
–
2
–
–
–
–
1

17
1
1
–
–
–
1
5
1
–
3
–
1
1
1
1
–

AZ, azithromycin; CL, chloramphenicol; CI, ciprofloxacin; CM,
clindamycin; EM, erythromycin; IP, imipenem; NA, nalidixic acid;
PM, cefepime; TC, tetracycline; TS, trimethoprim/sulfamethoxazole.
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Resistance to three or more antimicrobials was found in
28Æ4% (n ¼ 25) of the 88 multi-resistant isolates or 5Æ6% of
all isolates (Table 2). Significantly, seven times more C. coli
were found in this group compared with the C. jejuni strains
(20Æ9%, n ¼ 14 vs 2Æ9%, n ¼ 11; P < 0Æ05). Among the 11
resistance patterns found for those isolates resistant to three
or more antimicrobials, two were more common. Most
frequently observed was the combination of nalidixic acid,
tetracycline and trimethoprim/sulfamethoxazole resistance,
found in 28% (n ¼ 7) of these 25 strains (Table 2).
Resistance to ciprofloxacin, nalidixic acid and tetracycline
was observed in 24% (n ¼ 6) of this group. Moreover, a
single C. jejuni isolate was found to be resistant to seven
antimicrobials.
DISCUSSION
The use of antimicrobials in food animal production has
become a source of great controversy in recent years.
Concerns over the emergence of bacterial pathogens resistant to antimicrobials commonly used to treat infections in
humans, and the potential transfer of resistant pathogenic
strains from food products to humans has led to changes in
antimicrobial usage in livestock and poultry production
worldwide (Aarestrup and Wegner 1999; McEwen and
Fedorka-Cray 2002). Monitoring susceptibility patterns to
important antimicrobials among pathogens isolated from
food animal production sources is an essential component in
assessing risk associated with antimicrobial use in agriculture. Antimicrobial susceptibility was examined in Campylobacter isolated from US feedlot cattle. To date, this
livestock group has received relatively little attention in
antimicrobial resistance-monitoring studies.
A high level of resistance was observed to tetracycline,
exceeding 51% for the isolate group as a whole (Table 1).
This finding was not surprising as tetracyclines are
commonly used as injectable therapeutics for respiratory
disease, and as feed or water additives during the feedlot
stage of beef cattle production in the USA (USDA 2000).
Among the Campylobacter species, tetracycline resistance
was noticeably higher in C. coli, reaching nearly 66%
compared with 49Æ1% for C. jejuni. These numbers are
substantially higher than the average reported in a recent
multi-nation European study (Bywater et al. 2004) for
tetracycline resistance in C. coli (41Æ2%) and C. jejuni
(19Æ9%) from cattle. This may be a consequence of more
limited overall use of this drug in the countries that
provided the Campylobacter isolates (Germany, Italy and
the UK).
In contrast, although it has been estimated that only c.
0Æ3% of the cattle represented by the Feedlot 99 study
received sulfonamides in the feed or water, the overall
resistance to trimethoprim/sulfamethoxazole was 15Æ0%. A

study by Karmali et al. (1981) reported very high levels of
resistance to trimethoprim and sulfamethoxazole (100 and
85% of the isolates, respectively, at 32 lg ml)1) in C. jejuni
from human faecal isolates. Campylobacter jejuni has subsequently come to be regarded as endogenously resistant to
trimethoprim (Gibreel and Sköld 1998). Nonetheless,
resistance to trimethoprim/sulfamethoxazole among C.
jejuni in our study was only 8Æ4% (n ¼ 32) compared with
52Æ2% (n ¼ 35) for the C. coli strains (Table 1). Whether
this indicates a greater propensity for C. coli to acquire
resistance to trimethoprim/sulfamethoxazole compared with
C. jejuni remains to be determined, although it is again
reflective of the generally higher levels of resistance found in
C. coli (this study).
The fluoroquinolone enrofloxacin is approved for use in
the USA for the treatment of bovine respiratory disease in
cattle, and c. 32% of the feedlots in the Feedlot 99 study
reported using this antimicrobial therapeutically in some
cattle (USDA 2000). Still, resistance to ciprofloxacin, the
active metabolite of enrofloxacin, was only 2Æ9% overall,
although in C. coli resistance was 9Æ0% (Table 1). Feedlot
cattle are administered enrofloxacin as a single intramuscular
injection (http://www.fda.gov/cvm/greenbook.html). Concentrations of an injected fluoroquinolone reaching the gut
probably remain quite low. Resistance to ciprofloxacin was
one-fourth that of nalidixic acid (2Æ9 and 12Æ1% respectively), a finding similar to that described by Aarestrup et al.
(1997) for quinolone resistance in Campylobacter from cattle.
Among species, nalidixic acid resistance in C. coli was more
than twice that of C. jejuni (22Æ4% vs 10Æ2%). In contrast,
Bywater et al. (2004) found relatively high resistance to
ciprofloxacin in C. coli and C. jejuni from cattle (23Æ5 and
13Æ5% respectively), with comparable levels of resistance to
nalidixic acid.
A primary mechanism of resistance to quinolones in
Campylobacter involves discrete point mutations in the gyrA
gene, which encodes DNA gyrase (a type II topoisomerase)
(Drilca and Zhao 1997). In particular, the frequently
observed substitution Thr86-Ile in Campylobacter gyrA is
known to confer cross-resistance to both ciprofloxacin and
nalidixic acid (Wang et al. 1993; Gibreel et al. 1998).
Accordingly, 100% (n ¼ 13) of the ciprofloxacin-resistant
isolates were also resistant to nalidixic acid. However, 41
isolates (32 C. jejuni and nine C. coli), comprising 75Æ9% of
the 54 quinolone-resistant strains found in this study, were
resistant to nalidixic acid but did not show cross-resistance
to ciprofloxacin. The increased prevalence of nalidixic acid
resistance compared with ciprofloxacin was surprising,
considering that the feedlot cattle in this study were never
treated with nalidixic acid. In US broiler production,
enrofloxacin has been administered orally to flocks in the
drinking water to control and treat colibacillosis associated with E. coli infection (http://www.fda.gov/cvm/
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greenbook.html). Similarly, higher levels of resistance
to nalidixic acid compared with ciprofloxacin have
been reported for the NARMS Campylobacter poultry
isolates (http://www.ars-grin.gov/ars/SoAtlantic/Athens/
arru/narms.html), the source of which is broiler carcasses.
Bachoual et al. (2001) found that the Thr86-Ala gyrA
substitution in C. jejuni resulted in resistance to nalidixic
acid (MIC 64 lg ml)1) but not to ciprofloxacin (MIC
2 lg ml)1). This may explain the observed differences for
ciprofloxacin and nalidixic acid resistance, although other
mechanisms such as active efflux might also be involved.
Macrolides, in particular tilmicosin and tylosin, are also
frequently used in injectable form as therapeutics, and
tylosin was used as a feed or water additive on 20% of the
feedlots represented in the Feedlot 99 study of health and
management in US feedlots (USDA 2000). However,
resistance did not exceed 1Æ1% for the test group overall
to any of the three macrolide/lincosamide agents (azithromycin, clindamycin and erythromycin) included in this
study (Table 1). Cross-resistance to these antimicrobials in
strains resistant to tilmicosin or tylosin might be expected,
as discrete point mutations in the 23S rRNA gene appear to
be the primary mechanism involved in macrolide resistance
in Campylobacter (Engberg et al. 2001; Vacher et al. 2003).
Nonetheless, resistance to erythromycin, still considered a
drug of choice for treating Campylobacter infection, was only
0Æ9% overall (Table 1). Moreover, macrolide resistance was
far less than has been observed in Campylobacter from swine
(Aarestrup et al. 1997; Sáenz et al. 2000; Van Looveren
et al. 2001; Bywater et al. 2004), even though drugs of this
class are commonly used in both cattle and swine production. This indicates that even relatively high usage of
antimicrobials in particular class of food animals does not
necessarily lead to high levels of resistance to related
antimicrobials important in human medicine.
Although the use of chloramphenicol in livestock production has been banned for many years in the USA, a
fluorinated derivative, florfenicol, is approved for use in
treating respiratory disease in feedlot cattle. Of the feedlots
represented in the Feedlot 99 study, 54% used florfenicol as
a treatment for respiratory disease in some cattle, and 22Æ1%
used florfenicol metaphylactically to control shipping fever
in some cattle (USDA 2000). Cross-resistance to florfenicol
and chloramphenicol has been reported in E. coli (White
et al. 2000) and Salmonella (Bolton et al. 1999) resulting
from the acquisition of a unique gene termed flo. Resistance
to chloramphenicol in Campylobacter is most commonly
mediated by chloramphenicol acetyltransferase which inactivates the drug by acetylation (Wang and Taylor 1990).
This mechanism does not confer cross-resistance to florfenicol (Keyes et al. 2000). The lack of selective pressure by
florfenicol would account for the low overall resistance
(1Æ3%; Table 1) observed to chloramphenicol.
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The majority of Campylobacter isolates show resistance to
penicillins and narrow spectrum cephalosporins (Tajada
et al. 1996; Treiber and Taylor 2000), but this activity rarely
extends to the newer b-lactam agents. Consistent with this
observation, resistance to imipenem, cefepime and amoxicillin/clavulanic acid did not exceed 1Æ3% (Table 1)
although cephalosporins and penicillin/amoxicillin were
used in 8–38% of feedlots to treat some cases of respiratory
disease (USDA 2000).
Aminoglycosides, including gentamicin, are not generally
used to treat beef cattle in the USA, due to, in part, the long
duration of drug residues in some tissues. Not surprisingly,
only a single isolate among the 448 Campylobacter strains
included in this study was resistant to gentamicin.
Multiple resistance, including all isolates resistant to two
or more antimicrobials, was found more than three times as
often in the C. coli strains (49Æ3%; 33 of 67) compared with
the C. jejuni isolates (14Æ4%; 55 of 381). Moreover,
resistance to three or more antimicrobials, found in 5Æ6%
(25 of 448) of all isolates (Table 2), was over seven times
more common among the C. coli isolates (20Æ9%; 14 of 67)
compared with C. jejuni (2Æ9%; 11 of 381). Multidrug
resistance in Campylobacter has recently been reported to be
associated with the expression of the cmeABC efflux system
(Randall et al. 2003). While it may be speculated that this
system is expressed more often in certain Campylobacter
species such as C. coli, further work will be required to fully
explain this observation. Among the isolates resistant to
three or more antimicrobials, few patterns were apparent.
However, we noted that ciprofloxacin resistance in this
group was primarily associated with tetracycline resistance
(Table 2). This association has been seen in previous
studies, although the genetic basis has not been described
(Piddock 1995; Gaunt and Piddock 1996). Resistance to
macrolides among the multi-resistant isolates showed a
mixture of patterns. Specifically, resistance to azithromycin
and clindamycin or azithromycin and erythromycin was
observed, as well as resistance to only clindamycin or
erythromycin (Table 2). Only one strain in this group was
resistant to azithromycin, clindamycin and erythromycin, an
unusual C. jejuni isolate resistant to seven antimicrobials.
Although the mechanisms involved in macrolide resistance
in Campylobacter are not fully defined, cross-resistance to
azithromycin, clindamycin and erythromycin might have
been expected to be more commonly observed based on
previous reports (Engberg et al. 2001; Vacher et al. 2003).
In conclusion, despite the widespread use of antimicrobials in US feedlot cattle production, generally low levels of
antimicrobial resistance were observed in Campylobacter
isolated from this livestock source. A recent review of
European antimicrobial susceptibility surveillance results by
Bywater (2004) also noted that Campylobacter isolates from
cattle showed lower levels of resistance compared with
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broiler and swine carcass isolates. Tetracycline resistance
was an exception, although high levels of resistance to this
drug are often found in Campylobacter from food production
animals (e.g. Sáenz et al. 2000; Van Looveren et al. 2001;
Bywater et al. 2004). Some of the differences reported on
antimicrobial resistance in Campylobacter from various food
animal sources may be attributed to the susceptibility test
methods used (i.e. agar disk diffusion or agar dilution vs
E-test), and to differences in actual drug use practices. Even
so, obtaining antimicrobial resistance data from all food
animal groups is essential to the development and management of rational antimicrobial use practices in food animal
production.
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Gibreel, A. and Sköld, O. (1998) High-level resistance to trimethoprim
in clinical isolates of Campylobacter jejuni by acquisition of foreign
genes (dfr1 and dfr9) expressing drug-insensitive dihydrofolate
reductases. Antimicrob Agents Chemother 42, 3059–3064.
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